BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32388194)

  • 1. Validation of Gene Therapy for Mutant Mitochondria by Delivering Mitochondrial RNA Using a MITO-Porter.
    Kawamura E; Maruyama M; Abe J; Sudo A; Takeda A; Takada S; Yokota T; Kinugawa S; Harashima H; Yamada Y
    Mol Ther Nucleic Acids; 2020 Jun; 20():687-698. PubMed ID: 32388194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of a MITO-Porter to deliver exogenous therapeutic RNA to a mitochondrial disease's cell with a A1555G mutation in the mitochondrial 12S rRNA gene results in an increase in mitochondrial respiratory activity.
    Yamada Y; Maruyama M; Kita T; Usami SI; Kitajiri SI; Harashima H
    Mitochondrion; 2020 Nov; 55():134-144. PubMed ID: 33035688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [MITO-Porter; a cutting-edge technology for mitochondrial gene therapy].
    Furukawa R; Yamada Y; Harashima H
    Yakugaku Zasshi; 2012; 132(12):1389-98. PubMed ID: 23208046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a mitochondrial RNA therapeutic strategy using fibroblasts from a Leigh syndrome patient with a mutation in the mitochondrial ND3 gene.
    Yamada Y; Somiya K; Miyauchi A; Osaka H; Harashima H
    Sci Rep; 2020 May; 10(1):7511. PubMed ID: 32371897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of the MITO-porter, a nano device for mitochondrial drug delivery via membrane fusion].
    Yamada Y
    Yakugaku Zasshi; 2014; 134(11):1143-55. PubMed ID: 25366911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the Mitochondrial Genome Via a MITO-Porter : Evaluation of mtDNA and mtRNA Levels and Mitochondrial Function.
    Yamada Y; Harashima H
    Methods Mol Biol; 2021; 2275():227-245. PubMed ID: 34118041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial transgene expression via an artificial mitochondrial DNA vector in cells from a patient with a mitochondrial disease.
    Ishikawa T; Somiya K; Munechika R; Harashima H; Yamada Y
    J Control Release; 2018 Mar; 274():109-117. PubMed ID: 29408532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial matrix delivery using MITO-Porter, a liposome-based carrier that specifies fusion with mitochondrial membranes.
    Yasuzaki Y; Yamada Y; Harashima H
    Biochem Biophys Res Commun; 2010 Jun; 397(2):181-6. PubMed ID: 20580633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted mitochondrial delivery of antisense RNA-containing nanoparticles by a MITO-Porter for safe and efficient mitochondrial gene silencing.
    Kawamura E; Hibino M; Harashima H; Yamada Y
    Mitochondrion; 2019 Nov; 49():178-188. PubMed ID: 31472283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of bioactive molecules to the mitochondrial genome using a membrane-fusing, liposome-based carrier, DF-MITO-Porter.
    Yamada Y; Harashima H
    Biomaterials; 2012 Feb; 33(5):1589-95. PubMed ID: 22105068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial Delivery of an Anticancer Drug Via Systemic Administration Using a Mitochondrial Delivery System That Inhibits the Growth of Drug-Resistant Cancer Engrafted on Mice.
    Yamada Y; Munechika R; Satrialdi ; Kubota F; Sato Y; Sakurai Y; Harashima H
    J Pharm Sci; 2020 Aug; 109(8):2493-2500. PubMed ID: 32376272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial Delivery of Doxorubicin Using MITO-Porter Kills Drug-Resistant Renal Cancer Cells via Mitochondrial Toxicity.
    Yamada Y; Munechika R; Kawamura E; Sakurai Y; Sato Y; Harashima H
    J Pharm Sci; 2017 Sep; 106(9):2428-2437. PubMed ID: 28478130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the mitochondrial genome via a dual function MITO-Porter: evaluation of mtDNA levels and mitochondrial function.
    Yamada Y; Harashima H
    Methods Mol Biol; 2015; 1265():123-33. PubMed ID: 25634272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial delivery of antisense RNA by MITO-Porter results in mitochondrial RNA knockdown, and has a functional impact on mitochondria.
    Furukawa R; Yamada Y; Kawamura E; Harashima H
    Biomaterials; 2015 Jul; 57():107-15. PubMed ID: 25913255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial delivery of Coenzyme Q10 via systemic administration using a MITO-Porter prevents ischemia/reperfusion injury in the mouse liver.
    Yamada Y; Nakamura K; Abe J; Hyodo M; Haga S; Ozaki M; Harashima H
    J Control Release; 2015 Sep; 213():86-95. PubMed ID: 26160304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial delivery of bongkrekic acid using a MITO-Porter prevents the induction of apoptosis in human HeLa cells.
    Yamada Y; Nakamura K; Furukawa R; Kawamura E; Moriwaki T; Matsumoto K; Okuda K; Shindo M; Harashima H
    J Pharm Sci; 2013 Mar; 102(3):1008-15. PubMed ID: 23315986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MITO-Porter for Mitochondrial Delivery and Mitochondrial Functional Analysis.
    Yamada Y; Harashima H
    Handb Exp Pharmacol; 2017; 240():457-472. PubMed ID: 27830347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Mitochondrial Targeting Lipid Nanoparticle Encapsulating Berberine.
    Hori I; Harashima H; Yamada Y
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of membrane fusion between mitochondrial double membranes and MITO-Porter, mitochondrial fusogenic vesicles.
    Yamada Y; Fukuda Y; Harashima H
    Mitochondrion; 2015 Sep; 24():50-5. PubMed ID: 26188112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the Mitochondrial Delivery of Vitamin B
    Yamada Y; Ishimaru T; Ikeda K; Harashima H
    J Pharm Sci; 2022 Feb; 111(2):432-439. PubMed ID: 34478755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.